On Tuesday, Century Therapeutics Inc (NASDAQ: IPSC) opened higher 3.39% from the last session, before settling in for the closing price of $0.57. Price fluctuations for IPSC have ranged from $0.34 to $3.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 18.46%. Company’s average yearly earnings per share was noted 82.97% at the time writing. With a float of $40.60 million, this company’s outstanding shares have now reached $86.15 million.
Considering the fact that the conglomerate employs 150 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 100.0%, operating margin of -28.42%, and the pretax margin is -17.54%.
Century Therapeutics Inc (IPSC) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Century Therapeutics Inc is 52.88%, while institutional ownership is 28.86%. The most recent insider transaction that took place on Jun 09 ’25, was worth 3,050. In this transaction SVP Finance & Operations of this company sold 4,904 shares at a rate of $0.62, taking the stock ownership to the 405,982 shares. Before that another transaction happened on Jun 09 ’25, when Company’s Chief Operations Officer sold 552 for $0.62, making the entire transaction worth $343. This insider now owns 250,141 shares in total.
Century Therapeutics Inc (IPSC) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 82.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.86% during the next five years compared to 18.46% growth over the previous five years of trading.
Century Therapeutics Inc (NASDAQ: IPSC) Trading Performance Indicators
Check out the current performance indicators for Century Therapeutics Inc (IPSC). In the past quarter, the stock posted a quick ratio of 11.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.35 in one year’s time.
Technical Analysis of Century Therapeutics Inc (IPSC)
Compared to the last year’s volume of 0.63 million, its volume of 0.75 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 29.66%.
During the past 100 days, Century Therapeutics Inc’s (IPSC) raw stochastic average was set at 46.11%, which indicates a significant increase from 42.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.74% in the past 14 days, which was lower than the 67.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5520, while its 200-day Moving Average is $0.9584. Nevertheless, the first resistance level for the watch stands at $0.6063 in the near term. At $0.6180, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.6362. If the price goes on to break the first support level at $0.5764, it is likely to go to the next support level at $0.5582. Should the price break the second support level, the third support level stands at $0.5465.
Century Therapeutics Inc (NASDAQ: IPSC) Key Stats
There are currently 86,159K shares outstanding in the company with a market cap of 51.22 million. Presently, the company’s annual sales total 6,590 K according to its annual income of -126,570 K. Last quarter, the company’s sales amounted to 109,160 K and its income totaled 76,560 K.
